Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
The first choice for treatment of intermediate multiple liver cancer should be liver resection
2014-08-04
来源：转载自第三方
"Based on the careful selection of appropriate liver cancer patients, liver resection can significantly improve patient survival rate relative to interventional therapy (transcatheter arterial chemoembolization) for the ultra-Milan standard medium-term multiple liver cancer patients." Recently, the Second Military Medical University, Oriental Hepatobiliary Surgery Hospital Professor Zhou Weiping, who after a five-year randomized controlled clinical study, draw the above conclusions. Related paper has been published in the international journal "Journal of liver disease".
According to reports, the Milan standard is the world's most widely used to determine the standard of early liver cancer. Specifically, a single tumor diameter of no more than 5cm or tumors less than 3 and the largest diameter of is not more than 3cm, no major vascular invasion, no lymph nodes or extrahepatic metastasis, this is considered as early liver cancer, can benefit from liver transplantation treatment. 5-year survival rate of these patients is up to 75%, postoperative recurrence rate is generally less than 10%. The Barcelona clinical staging formed by the European Liver Research Society in 1999 is clearly suggested that interventional therapy is the best treatment for patients with intermediate liver cancer.
Of the 2502 patients with hepatocellular carcinoma who underwent radical hepatectomy, Zhou Weiping screened 173 patients with medium-term multiple hepatocellular carcinoma of the super-Milan standard, and randomized clinical control study, 88 of them entered the hepatectomy group and 85 patients entered the intervention group. 32-month follow-up survival analysis showed that the median survival time was 41 months and 14 months, respectively in both groups undergoing hepatectomy and interventional therapy. Further analysis showed a 56.6% reduction in the risk of liver cancer-related death in patients undergoing hepatectomy. A large number of international studies have shown that patients with intermediate multiple liver cancer after interventional therapy, the median survival time is about 20 months previously.
The research are in strict accordance with international standards in the experimental design, patient enrollment, statistical analysis and other aspects, the final conclusion of the study has been recognized by the international peer experts. It laid the foundation for the diagnosis and treatment of liver cancer suitable for China.
TAG: Chemical Reagents, Biomedicine
如果涉及转载授权，请联系我们。
